12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Maestro Rechargeable: Pivotal trial data

Top-line data from 239 patients in the intent-to-treat (ITT) population of the double-blind, U.S. and Australian ReCharge pivotal trial showed that VBLOC vagal blocking therapy delivered with the company's Maestro RC System missed the co-primary endpoints of 55% of patients achieving >=20% EWL and 45% of patients achieving >=25% EWL (52.5% and 38.3%, respectively). EnteroMedics said the differences on both endpoints were significant...

Read the full 295 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >